ImetelChat

Method for eliciting an immune response to human telomerase reverse transcriptase (15 September 2016) Inventors: Thomas R. Cech, Joachim Lingner, Toru M. Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews The invention provides compositions and methods related to human...

Things are slowly accumulating. New patents, extended licensing agreement, trials keep going, no new safety issues, encouraging trends observed, new trial sites opened, Gryaznov speaking about imetelstat on behalf of JnJ... Silence until Q2 2017? Don't think so.

If we find something, it will be posted here!

Sergei Gryaznov, a former employee of Geron and now working for Alios/JnJ, is presenting about imetelstat at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society on September 25-28, 2016. Gryaznov is the co-inventor of many Geron patents regarding imetelstat. Imetelstat - First in Cla...

Good sign.

Bio: indeed, it could. But I believe it was said that the internal interim review was not looking at the primary end-points, after an analyst asked for the criteria.

Rob: that remains guessing, because they won't tell. They didn't tell it in the cc, not in the press release and not in the answers of the various questions. My guess is that we have to look into hematological responses (lower LDH, less inflammation, improved blood counts etc.). I don't think they w...

Intersting: the to arms 'likely be analyzed independently'. So it is not 100% sure they will. She also says implicitely that the former 4.7 arm will stay part of the trial. That means that all original cohort of patients are staying on the trial.

(received 19 September 1016, based on some questions I had sent to her before) Thank you for your feedback, it is always appreciated. I would like to clarify a couple of points. Enrollment of new patients to the 9.4 mg/kg arm has been suspended, while the trial continues in order to obtain additiona...

Nice article about JnJ - Geron partnership: Janssen Builds On Partnership With Geron Corporation By Andy Parker - September 21, 2016 Janssen Pharmaceuticals, a subsidiary of the giant manufacturing company, Johnson & Johnson (NYSE:JNJ) has expanded the current partnership with the long-beleaguered G...

Irish and Bio, thanks for your great comments!

Form the 8-K filed by Geron: 1.01 Entry into a Material Definitive Agreement. On September 15, 2016 (the “Execution Date”), Geron Corporation (“Geron” or the “Company”) and Janssen Pharmaceuticals, Inc. (“Janssen Pharmaceuticals”), entered into a license agreement (the “License Agreement”) granting ...

Cheng: the PRs/CRs observed by Mayo seemed to be exciting enough for JnJ. So probably you are missing something here. I also must say that I am a bit suprised that you are heavily commenting on all these message boards with all kinds of strong opinions, while not being excited about imetelstat. It i...

Not sure if being right or wrong is a useful question. There is a very complex game going on. We know who was right or wrong afterwards. I also have always have wondered why IMerge doesn't seem to add value. But it is as it is. The market is always right, also if it is wrong. But as long as the tria...

Hi Sargasso, these are impressive figuers, including the MDS market growth rate of 10-12%. For some reason there always has been a kind of focus on MF, maybe because cleaning the bone marrow is very scpetacular. But in fact we don't discuss MDS a lot. That IMerge is still meeting expectations is ver...

(From Nosy, posted on SA, 15 September 2016) Thank you for your email and commentary. We did put out a press release with information we can include. We stated that encouraging trends were observed in the efficacy data of the 9.4mg/kg arm in the myolefibrosis trial. We will now wait for longer follo...

bio: the article needs to purchased, which I haven't done (yet). Maybe I will ask a medical friend if he has access to it.

Makes sense, bp. The data were encouraging enough for JnJ to 1) keep the trial going and 2) move over the 4.7 to the 9.4 arm. Even after this short period of time. All this negativity is really strange. The positive is that we have a buying opportunity. Absolutely no reason for me to sell. I can ima...

Great post, great info! Thanks for that! Question: which Tefferi article do you mean? Do you have title/link? Primary vs secondary end-points: it is quite intriguing that all the talk is about the co-primary end-points, while the real story is being told in the secondary end-points. And that is exac...

Great post from Magictuzi on SA 13 September 2016), which to my opinion nails down the essence of the CC: I agree that Scarlet should have said it differently but it's easier said than done. What's the reality now? My previous posts stated that they would probably ditched the 4.7 dosage and move to ...